|
|
||||||||



,||
,1
* Department of Physiology and Pharmacology and
Department of Surgical Sciences at the Karolinska Institutet, Stockholm, Sweden;
Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden;
Department of Medical Biochemistry and Microbiology and the
|| Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, Uppsala University, Uppsala Biomedical Center, Uppsala, Sweden
1 Correspondence: Karolinska Institutet, Department of Surgical Sciences, Section of Integrative Physiology, von Eulers väg 4, 4th Floor, S-171 77 Stockholm, Sweden. E-mail: Juleen.Zierath{at}fyfa.ki.se
| ABSTRACT |
|---|
|
|
|---|
3 subunit (Prkag3225Q) increases AMPK activity and skeletal muscle glycogen content. Transfection experiments revealed the R225Q mutation is associated with high basal AMPK activity and diminished AMP dependence. Thus, the R225Q mutation can be considered a loss-of-function mutation that abolished allosteric regulation by AMP/ATP, causing increased basal AMPK activity. We used AMPK
3 transgenic (Tg-Prkag3225Q) and knockout (Prkag3/) mice to determine the relationship between AMPK activity, glycogen content, and ergogenics (ability to perform work) in isolated extensor digitorum longus skeletal muscle after contractions induced by electrical stimulation. Contraction-induced AMPK activity was inversely coupled to glycogen content in wild-type and Tg-Prkag3225Q mice, but not in Prkag3/ mice, highlighting a partial feedback control of glycogen on contraction-induced AMPK activity in the presence of a functional AMPK
3 isoform. Skeletal muscle glycogen content was positively correlated to work performance, regardless of genotype. Thus, chronic activation of AMPK by the Prkag3225Q mutation directly influences skeletal muscle ergogenics by enhancing glycogen content. In conclusion, functional studies of the AMPK
3 isoform further support the close connection between glycogen content and exercise performance in skeletal muscle.Barnes, B. R., Glund, S., Long, Y. C., Hjälm, G., Andersson, L., Zierath, J. R. 5'-AMP-activated protein kinase regulates skeletal muscle glycogen content and ergogenics.
Key Words: muscle ergogenics AMPK activity allosteric regulation EDL glycogen supercompensation
| INTRODUCTION |
|---|
|
|
|---|
Exercise induces an insulin-independent effect on glucose uptake, which partly accounts for rapid glycogen resynthesis in the recovery phase (2
, 3)
. This "exercise effect" on glucose transport persists until muscle glycogen levels are restored (2
, 4)
, indicating a feedback regulation of glycogen on glucose transport. Although the acute effects of exercise on substrate utilization has been a topic of great interest, the signaling pathways by which muscle contraction promotes glycogen resynthesis are incompletely described. Historically, glycogen synthase has been highlighted as a major regulatory step in glycogen resynthesis in response to exercise. Functional studies in transgenic mice whereby glycogen synthase has been overexpressed in skeletal muscle provide evidence that the level of glycogen synthase activity has a positive impact on glycogen content (5)
. Moreover, under physiological conditions such as strenuous exercise, the rate of glycogen repletion is positively correlated with glycogen synthase activity (6)
. However, exercise-induced signaling pathways to glycogen synthase are unknown. Recent evidence places the 5'AMP-activated protein kinase (AMPK) signaling cascade upstream of glycogen synthase (7
, 8)
. Thus, AMPK may be involved in post-exercise glycogen resynthesis.
AMPK is a heterotrimeric protein composed of one catalytic (
) and two noncatalytic (ß and
) subunits that, when activated, stimulates catabolic processes to produce ATP (9)
. Exercise increases AMPK activity in skeletal muscle (10)
, with greatest effects occurring when glycogen levels are low (11
, 12)
. Thus, AMPK activation appears to be intimately linked to the pre-exercise fuel status of skeletal muscle irrespective of changes in energy status (11
, 12)
. The molecular link between AMPK and glycogen content has been directly established through genetic studies. Overexpression of a kinase dead AMPK
2 isoform or ablation of the
3 subunit is associated with impaired glycogen resynthesis in skeletal muscle (13
, 14)
. In contrast, naturally occurring mutations in the
2 and
3 subunit isoforms increase glycogen storage in human heart and pig skeletal muscle, respectively (15)
. The increase in muscle glycogen that occurs as a consequence of mutations in the
3 isoform may enhance glycogen storage by shifting the metabolic fate of glucose from oxidation to storage, but this is unexplored.
The relationship between AMPK activation, glycogen content, glucose utilization, and muscle ergogenics (the ability to perform work) remains unclear. We previously reported that the dominant missense mutation (R225Q) identified in pig PRKAG3 encoding the muscle-specific
3 isoform causes a marked increase in glycogen content (16)
. Transfection experiments revealed the R225Q mutation is associated with high basal AMPK activity and diminished AMP dependence (13)
. Thus, the R225Q mutation can be considered a loss-of-function mutation that abolishes allosteric regulation by AMP/ATP, causing increased basal AMPK activity. Here we provide evidence that glycogen supercompensation requires expression of the AMPK
3 isoform in the fed state. Moreover R225Q mutation promotes a shift in glucose metabolism from oxidation to storage in response to exercise. The elevated muscle glycogen provides an ergogenic benefit by increasing performance directly in working muscle.
| MATERIALS AND METHODS |
|---|
|
|
|---|
3 subunit (Tg-Prkag3225Q); knockout mice, whereby the Prkag3 gene has been ablated (Prkag3/); and wild-type littermates. The general metabolic characteristics of these animal models have been described (13)
In vitro muscle contraction
EDL muscles were mounted in a temperature-controlled (30°C) incubation chamber, positioned between two platinum electrodes and immersed in media (13
, 17)
. The proximal tendon was connected to an isometric force transducer (Harvard Apparatus, South Natick, MA, USA). One muscle from each animal was stimulated at 100 Hz (0.2 ms pulse duration, 20 V) at a rate of one 0.2 s contraction every 2 s for 10 min (18)
. The contralateral muscle was incubated under resting (nonstimulated) conditions. Incubations were terminated by immediate freezing of the muscle in liquid nitrogen. Muscles were stored at 80°C.
Total AMPK activity
Kinase assays were performed as described (19)
. pan-AMPK antiserum raised against bacterially expressed
1,
2, ß1, ß2, and
1 protein (generous gift from David Carling, Imperial College, Hammersmith Hospital, London, UK) was used to precipitate total AMPK protein. Five µL pan-AMPK antiserum prebound to 20 µL protein A-Sepharose (50% slurry; Amersham Biosciences, Uppsala, Sweden) was used to immunoprecipitate the kinase from skeletal muscle lysate (200 µg protein) at 4°C for 3 h. Total AMPK activity was determined in the washed immune complex using SAMS peptide as substrate. Complexes were incubated in assay buffer for 45 min at 30°C. Incorporation of [32P]-ATP into the peptide was measured by liquid scintillation counting of sample aliquots spotted on P81 paper (Whatman International, Maidstone, UK).
Glycogen content
Glycogen content was determined fluorometrically on HCl extracts (20)
.
Skeletal muscle fatigue
During in vitro electrical stimulation, the force of contraction generated by the muscle was measured, quantified by an isometric force transducer (Harvard Apparatus), and recorded with an oscilloscope. Peak force (initial contraction) generation was recorded for each muscle. Thereafter, muscle fatigue was determined by measuring the time expired before force generation equaled 50% of the peak force.
Glucose oxidation
Muscles were incubated at 30°C for 60 min in incubation media described above, supplemented with [14C]-glucose (0.2 mCi/mL), as described (21)
. Thereafter, 0.2 mL solvent was injected into the center well of the incubation flask and 0.5 mL of 15% perchloric acid was injected into the incubation media. Glucose oxidation was assessed by collection of liberated [14C]O2.
Statistical analysis
A difference between groups was determined by ANOVA with multiple comparisons for AMPK activity. Students t test was used for all other analyses. Significance was accepted at P <0.05. Relationships were determined by linear correlation and regression analysis.
| RESULTS |
|---|
|
|
|---|
|
Glycogen content
Glycogen content in EDL muscle was assessed at rest and after in vitro contraction, under fed and fasted conditions (Table 2
). In vitro contraction reduced glycogen content
50% (P<0.05) in EDL muscle, regardless of genotypes, under either nutritional state. Moreover, in Tg-Prkag3225Q mice, glycogen content was higher at rest (>60%; P<0.05) and after in vitro contraction (>50%, P<0.05) compared with wild-type and Prkag3/ mice regardless of nutritional state. In fed and fasted Prkag3/ mice, glycogen content was
35% (P<0.05) lower at rest compared with wild-type mice. Regardless of nutritional state, however, glycogen content in EDL muscle from Prkag3/ mice after contraction was similar to that of wild-type mice.
|
Relationship between AMPK activity and glycogen content
In wild-type and Tg-Prkag3225Q mice, an inverse correlation between AMPK activity and glycogen content was observed (Fig. 1
, R2 = 0.63 and 0.64, respectively). This supports the concept that glycogen has a feedback regulation on AMPK activity. In Prkag3/ mice, however, glycogen content and AMPK activity were unrelated (R2 = 0.36), indicating that expression of the AMPK
3 isoform is necessary for glycogen feedback on AMPK.
|
Skeletal muscle fatigue
Resistance to skeletal muscle fatigue was determined in EDL muscle after electrical stimulation. Fatigue was measured as the time elapsed until 50% of the peak force was generated (Fig. 2
A). EDL muscles from Tg-Prkag3225Q mice were fatigue resistant, as demonstrated by an increased ability to sustain work compared with wild-type mice (difference=+0.21±0.06 min, P<0.002 in an ANOVA analysis combining data from fed and fasted mice). In contrast, EDL muscle from Prkag3/ mice were fatigue prone and had a decreased time to fatigue (difference =0.17±0.07 min; P<0.02 vs. wild-type mice in an ANOVA analysis combining data from fed and fasted mice). Time to fatigue was similar in Prkag3/ and wild-type mice under fasting conditions. Skeletal muscle fatigue was positively correlated with glycogen content (Fig. 2B
, R2=0.79).
|
Glucose oxidation
Glucose oxidation was determined after in vitro contraction of EDL muscles from fasted mice (Fig. 3
). In Tg-Prkag3225Q mice, glucose oxidation was reduced 45% (P<0.05) after in vitro contraction. Conversely, glucose oxidation was increased 44% (P<0.05) in Prkag3/ mice after in vitro contraction.
|
| DISCUSSION |
|---|
|
|
|---|
3 subunit.
We have previously reported that heterotrimeric complexes containing the AMPK
3 R225Q mutation result in an increase in AMPK activity and phosphorylation on Thr172 in an AMP-independent manner and diminished AMP dependence in transfected Cos cells (13)
. Thus, the R225Q mutation is a loss-of-function mutation that abolishes allosteric regulation by AMP/ATP, which is predicted to increase basal AMPK activity. Nevertheless, in rested muscle from Tg-Prkag3225Q mice AMPK activity was unaltered. In fed AMPK R225Q mutant pigs, AMPK activity was reduced (16)
. While these results are paradoxical, the excessive skeletal muscle glycogen content in Tg-Prkag3225Q mice and AMPK R225Q mutant pigs may feed back and inhibit AMPK activity. Several lines of evidence suggest high glycogen content inhibits AMPK activity in skeletal muscle (11
, 22
, 23)
. Therefore, a plausible explanation for the lack of a further elevation in AMPK activation in Tg-Prkag3225Q vs. wild-type mice can be attributed to the 70% higher glycogen content. Although we are unable to biochemically distinguish the AMPK associated with different gamma isoforms, when muscle glycogen levels are depleted in Tg-Prkag3225Q mice, contraction-induced AMPK activity is increased. In contrast, the reduction in AMPK activity after contraction in fed Prkag3/ mice is unrelated to glycogen content and suggests that the
3 subunit is responsible for the major proportion of contraction-induced AMPK activation. However, under fasted conditions, contraction-induced AMPK activity is unaltered in Prkag3/ mice, possibly a consequence of a more general AMPK activation in the energy-deprived fasted muscle. Moreover, glycogen content is negatively correlated with AMPK activity in wild-type and Tg-Prkag3225Q mice, but not in Prkag3/ mice (Fig. 1)
, highlighting the potential importance of the
3 isoform in glycogen feedback on AMPK.
Several lines of evidence indicate AMPK is a glycogen synthase kinase; thus, active AMPK would be predicted to prevent glycogenesis in skeletal muscle. AMPK phosphorylates and inactivates muscle glycogen synthase in cell-free assays at site 2 (24)
. In vivo, AMPK is a glycogen synthase kinase in skeletal muscle in response to AICAR stimulation (23)
and exercise (25)
, phosphorylating site 2 and leading to inactivation of glycogen synthase. AMPK activity is negatively correlated with glycogen synthase activity during exercise (7)
; thus, active AMPK should prevent glycogenesis in skeletal muscle. In vivo, however, the effect of AMPK activation on glycogensynthase may also be indirectly regulated through the action of other glycogen synthase phosphatases or kinases (25)
. AICAR and exercise activate AMPK and inactivate glycogen synthase (23
, 25)
while simultaneously activating glucose transport (26
, 27)
. The effects of AICAR or exercise on glucose transport may predominate and facilitate, rather than retard, glycogenesis through increased cellular levels of glucose-6-phosphate, which may override any inhibitory phosphorylation of glycogen synthase by allosteric activation. In support of this hypothesis, treatment of animals with AICAR actually increases skeletal muscle glycogen content (27
, 28)
. Moreover, in transgenic mice overexpressing a kinase-dead AMPK
2 subunit (
2KD) and AMPK
2 knockout mice, AMPK activity is severely blunted, and glycogen levels (14
, 17)
and rates of resynthesis after exercise (29)
are markedly impaired. Similarly, skeletal muscle glycogen levels (Table 2)
and rates of resynthesis after exercise are blunted in Prkag3/ mice (13)
.
AMPK has been linked to exercise tolerance and performance (14
, 29)
. AMPK
2KD mice have decreased spontaneous physical activity as determined by volunteer wheel running and increased muscle fatigue in response to repeated electrical stimulation of isolated muscle (14
, 29)
. Here we report modification of the AMPK
3 subunit influences muscle ergogenics. Work performance is enhanced in skeletal muscle from Tg-Prkag3225Q mice under fed and fasted conditions. In contrast, skeletal muscle from Prkag3/ mice is fatigue prone during exercise. Based on in vitro observations in isolated skeletal muscle, we provide evidence that the AMPK
3 isoform enhances muscle ergogenics by altering glycogen levels and that this effect is independent of capillary density or serum factors. Moreover, the enhanced work performance in Tg-Prkag3225Q mice is independent of fiber type changes (13)
. It is interesting that work performance in Tg-Prkag3225Q, Prkag3/, and wild-type mice was positively correlated to the level of skeletal muscle glycogen. Thus, the increase in glycogen content, rather than AMPK per se, is a major determinant of anaerobic muscle performance.
To determine the role of the AMPK
3 isoform on glycogenesis after anaerobic exercise, we measured glycogen resynthesis rates at 2.5 and 6 h of recovery after in vitro contraction (data not shown). However, glycogen resynthesis was minimal under these conditions. Since the early phase glycogen resynthesis is slow after eccentric and high-intensity resistance exercise (30
, 31)
, the minimal glycogen synthesis rate after in vitro contraction would be expected. After moderate exercise, such as swimming in Tg-Prkag3225Q mice (13)
or treadmill running in AMPK R200Q pigs (16)
, the rate of glycogen resynthesis is rapidly increased than wild-type animals. In contrast,
2KD mice and Prkag3/ mice have lower resting glycogen content and defects in glycogen resynthesis after exercise compared with wild-type mice (14
, 29)
. Together, these findings support the functional role of AMPK and highlight
3 containing complexes in mediating glycogenesis after exercise.
To investigate glucose handling after glycogen-depleting contraction, we used indirect methods to determine the potential for glycogen resynthesis. Once glucose is transported across the plasma membrane, the glycolytic fate of glucose is oxidation or glycogen synthesis. We have previously reported that glucose uptake after electrically stimulated muscle contraction is similar among Tg-Prkag3225Q, Prkag3/, and wild-type mice (13)
. This would suggest that alterations in glucose handling partly contribute to the changes in glycogen content in genetically modified AMPK
3 mice. Indeed, glucose oxidation was markedly reduced in Tg-Prkag3225Q mice and increased in Prkag3/ mice. This observation is further supported by the finding that Tg-Prkag3225Q and Prkag3/ mice have a reciprocal rate of glycogen resynthesis after an endurance bout of exercise (13)
.
In conclusion, the Prkag3225Q mutation increases skeletal muscle ergogenics by enhancing glycogen content. Moreover, in response to anaerobic exercise, the Prkag3225Q mutation suppresses glucose oxidation and facilitates glycogenesis. The AMPK
3 isoform has intrinsic control over anaerobic exercise responses, since ablation of the isoform influences glucose metabolism and muscle ergogenics. Functional studies of the AMPK
3 isoform further support the close connection between glycogen content and exercise performance in skeletal muscle.
| ACKNOWLEDGMENTS |
|---|
Received for publication October 5, 2004. Accepted for publication January 7, 2005.
| REFERENCES |
|---|
|
|
|---|
3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J. Biol. Chem. 279,38441-38447
2 but not
1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-ß-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279,1070-1079
2 5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes 53,3074-3081This article has been cited by other articles:
![]() |
M. E. Osler and J. R. Zierath Minireview: Adenosine 5'-Monophosphate-Activated Protein Kinase Regulation of Fatty Acid Oxidation in Skeletal Muscle Endocrinology, March 1, 2008; 149(3): 935 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Folmes, L. A. Witters, M. F. Allard, M. E. Young, and J. R. B. Dyck The AMPK {gamma}1 R70Q mutant regulates multiple metabolic and growth pathways in neonatal cardiac myocytes Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3456 - H3464. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Klein, H. Pilegaard, J. T. Treebak, T. E. Jensen, B. Viollet, P. Schjerling, and J. F. P. Wojtaszewski Lack of AMPK{alpha}2 enhances pyruvate dehydrogenase activity during exercise Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1242 - E1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Jaswal, M. Gandhi, B. A. Finegan, J. R. B. Dyck, and A. S. Clanachan Inhibition of p38 MAPK and AMPK restores adenosine-induced cardioprotection in hearts stressed by antecedent ischemia by altering glucose utilization Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1107 - H1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Barre, C. Richardson, M. F. Hirshman, J. Brozinick, S. Fiering, B. E. Kemp, L. J. Goodyear, and L. A. Witters Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E802 - E811. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu, M. F. Hirshman, N. Fujii, J. M. Pomerleau, L. E. Peter, and L. J. Goodyear Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase {gamma}3-subunit differentially regulates glycogen accumulation Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E557 - E565. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Treebak, S. Glund, A. Deshmukh, D. K. Klein, Y. C. Long, T. E. Jensen, S. B. Jorgensen, B. Viollet, L. Andersson, D. Neumann, et al. AMPK-Mediated AS160 Phosphorylation in Skeletal Muscle Is Dependent on AMPK Catalytic and Regulatory Subunits. Diabetes, July 1, 2006; 55(7): 2051 - 2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Jorgensen, E. A. Richter, and J. F. P. Wojtaszewski Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise J. Physiol., July 1, 2006; 574(1): 17 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Nilsson, Y. C. Long, S. Martinsson, S. Glund, P. Garcia-Roves, L. T. Svensson, L. Andersson, J. R. Zierath, and M. Mahlapuu Opposite Transcriptional Regulation in Skeletal Muscle of AMP-activated Protein Kinase {gamma}3 R225Q Transgenic Versus Knock-out Mice J. Biol. Chem., March 17, 2006; 281(11): 7244 - 7252. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Hardie and K. Sakamoto AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle Physiology, February 1, 2006; 21(1): 48 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Barnes, Y. C. Long, T. L. Steiler, Y. Leng, D. Galuska, J. F.P. Wojtaszewski, L. Andersson, and J. R. Zierath Changes in Exercise-Induced Gene Expression in 5'-AMP-Activated Protein Kinase {gamma}3-Null and {gamma}3 R225Q Transgenic Mice Diabetes, December 1, 2005; 54(12): 3484 - 3489. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |